AstraZeneca finds small clot risk after 1st shot of COVID-19 vaccine
Fox News
A study conducted by AstraZeneca regarding its COVID-19 vaccine found a small risk of blood clots following the first dose of the shot, but none after the second jab.
The shot’s rollout worldwide has been marred by pauses and advisories regarding the potential risk of blood clots in recipients, prompting some countries to recommend using it only in certain populations. The two-dose jab has not yet been approved for use in the U.S. AstraZeneca said Wednesday in a news release that rates of thrombosis with thrombocytopenia (TTS) following the first dose of Vaxzevria were about 8.1 per million vaccines, while the rates following a second dose were 2.3 per million, "comparable to the background rate observed in an unvaccinated population."More Related News